All In Biotech

Drug Trial Radar · NCT05431153

A Study to Investigate the Effect of Tablet Formulation and Food on PF-07104091 in Healthy Participants

A PHASE 1, RANDOMIZED, OPEN-LABEL, 4-PERIOD, 5-TREATMENT, 6-SEQUENCE, CROSSOVER, SINGLE-DOSE STUDY IN HEALTHY PARTICIPANTS TO INVESTIGATE THE EFFECT OF TABLET FORMULATION AND FOOD ON THE BIOAVAILABILITY OF PF-07104091

Last checked: Nov 20, 2026Latest source record: Apr 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

30

Actual

Start

Jun 10, 2022

Primary completion

Oct 17, 2022

Study completion Oct 17, 2022

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jun 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single dose crossover pharmacokinetic (pharmacokinetics helps in understanding how the drug is changed and eliminated from the body after a participant takes it) study in healthy participants. The study consists of 5 treatments, and each participant will be randomized to receive 4 of the treatments in separate periods in a specific sequence. Each treatment consists of a single dose of PF-07104091 and the treatments differ by tablet formulation and/or whether the dose is to be given under fasted or fed conditions. Plasma pharmacokinetics of PF-07104091 will be assessed following each dose to determine the effect of tablet formulation and fed condition on the relative bioavailability of PF-07104091.

Conditions

  • Healthy

Interventions

  • Single dose of PF-07104091 as Tablet Formulation A (Treatment A)Drug

    A single dose of PF-07104091 as Tablet Formulation A administered under fasting conditions.

  • Single dose of PF-07104091 as Tablet Formulation B (Treatment B)Drug

    A single dose of PF-07104091 as Tablet Formulation B administered under fasting conditions.

  • Single dose of PF-07104091 as Tablet Formulation C (Treatment C)Drug

    A single dose of PF-07104091 as Tablet Formulation C administered under fasting conditions.

  • Single dose of PF-07104091 as Tablet Formulation D (Treatment D)Drug

    A single dose of PF-07104091 as Tablet Formulation D administered under fasting conditions.

  • Single dose of PF-07104091 as Tablet Formulation C (Treatment E)Drug

    A single dose of PF-07104091 as Tablet Formulation C administered under fed conditions.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Plasma-Concentration Time Curve From Time Zero (0) Extrapolated to Infinity (AUCinf) of PF-07104091 for Treatment A, B, and CTime frame: Predose, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
  2. Maximum Observed Plasma Concentration (Cmax) of PF-07104091 for Treatment A, B and CTime frame: Predose, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • New Haven Clinical Research Unit

    New Haven, Connecticut

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.